



Several populations of stem cells exhibit migratory activity that is an essential component of their regenerative capacity. In
this issue, two papers explore migratory progenitor populations from different perspectives. In the first case, Franz and
colleagues utilize a mobilization strategy originally developed for the hematopoietic system and combine it with a selective
inhibitor to promote cardiac localization of endothelial precursors recruited from the marrow.
SDF-dependent recruitment of EPCs to the heart leads to improved vascular regeneration
and survival in this animal model and highlights how advances in one lineage can be adapted
for application to alternate therapeutic designs. Like the adult heart, articular cartilage within
human joints has also been considered refractory to significant and long-term repair. Miosge
and coauthors provide evidence, however, for the presence of a migratory chondrogenic
progenitor population that can be isolated from human osteoarthritic joints. The identification
of this cartilage-forming pool within diseased tissue and the observation that runx-2 partici-
pates in regulating chondrogenic potential offer an exciting opportunity to study, and possibly
harness, migratory progenitors in this lineage as well.Regulating Pluripotency In Vitro, in Patients, and across Countries
Human ESCs, with their theoretically unlimited potential for proliferation, provide a significant source of cellular building
blocks for regenerative medicine, particularly if directed differentiation can be accomplished in an efficient and homogeneous
fashion. In this issue, Melton and colleagues describe a drug screening strategy that identified two chemicals that promote
endoderm generation from both mouse and human ESCs. The resulting population, which closely resembles its in vivo coun-
terpart, offers an important step toward the goal of producing progenitors that are therapeutically relevant in both number and
function. Despite the advances in directing the development of lineage-constrained progenitors and differentiated cells from
pluripotent populations, transfer of hESC-derived cells into patients remains a potentially dangerous endeavor. Also in this
issue, Crystal and coauthors outline their Perspective—informed by decades of experience in gene therapy initiatives—to
propose various genetic means to exert control over any wayward pluripotent cells or derivatives that threaten the recipient
of a future hESC-transplant-based therapy. Given that, in the US, the FDA has recently approved measures that will see
hESCs transplanted into patients in a therapeutic trial, safety issues will remain under close scrutiny as pluripotent cells
and their progeny are used in clinical settings. Also in the US, the recent announcement by the Obama administration to over-
rule funding restrictions on newly generated hESCs suggests that many more research groups will soon be embarking
on related studies. Clearly, researchers and regulatory bodies that develop legislation and policies overseeing the derivation
and use of pluripotent populations will need to work together closely to ensure that appropriate oversight is attained,
while also allowing for innovation and potentially unpredictable scientific advances. This thesis is outlined in a Forum
article from Caulfield, Rossant, and colleagues, who use the existing legislative climate in Canada as a framework for their
discussion.Reprogramming on Drugs
The reprogramming field continues to move at a blistering pace, and this issue includes a Review article from Ng and
coauthors that overviews recent iPSC reprogramming advances that make use of small molecules as well as alternate genetic
factors. The authors also discuss how screening protocols may uncover additional drugs, such as kinase inhibitors and
epigenetic modifiers, that will replace the genetic factors currently utilized to induce pluripotency. In addition to promoting
somatic cell reprogramming, existing pluripotent populations are heterogeneous and can be altered without genetic modifi-
cations, as demonstrated by Blau and colleagues. In their study, the authors expose mouse and human ESCs to histone
deacetylators to toggle between phenotypic and functional pluripotent populations. Their findings underscore the potential
for extracellular inputs to perturb stem cell fates. Differentiation potential can also be impacted by cell-to-cell contacts,
and the cumulative environmental signals surrounding an individual cell may lead to a modified form of somatic cell reprog-
ramming to produce cancer stem-like cells, as demonstrated by Liu et al. The authors reveal
that, if normal fibroblasts are forced to grow in suspension, the resulting spheres contain
cells that express hallmarks of nonfibroblastic differentiation, and even markers associated
with multipotent stem cells. Further, spheres form spontaneously when contact inhibition
processes are lost in the absence of Rb family genes. Finally, Rb-deficient sphere-derived
cells are able to generate differentiated tumors in vivo, highlighting that at least some
degree of functional reprogramming has occurred within the fibroblast-derived culture. It
remains to be seen whether fully reprogrammed, pluripotent cells arise during this culturing
process, but the ability to generate tumor-forming cells of alternate lineages simply by
promoting modified cell-cell interactions raises interesting questions indeed.Cell Stem Cell 4, April 3, 2009 ª2009 Elsevier Inc. xvii
